Compare INTS & GENK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INTS | GENK |
|---|---|---|
| Founded | 2012 | 2011 |
| Country | United States | United States |
| Employees | N/A | 2700 |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4M | 12.8M |
| IPO Year | 2021 | 2023 |
| Metric | INTS | GENK |
|---|---|---|
| Price | $4.04 | $1.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $38.00 | $4.50 |
| AVG Volume (30 Days) | 25.0K | ★ 111.5K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | ★ 1.88% |
| EPS Growth | N/A | ★ 62.50 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $208,380,000.00 |
| Revenue This Year | N/A | $4.79 |
| Revenue Next Year | N/A | $7.48 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 15.12 |
| 52 Week Low | $0.22 | $1.43 |
| 52 Week High | $8.06 | $3.44 |
| Indicator | INTS | GENK |
|---|---|---|
| Relative Strength Index (RSI) | 41.36 | 46.18 |
| Support Level | $3.99 | $1.73 |
| Resistance Level | $5.00 | $2.48 |
| Average True Range (ATR) | 0.28 | 0.14 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 23.74 | 18.87 |
Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.
GEN Restaurant Group Inc operates an Asian casual dining restaurant chain, offering an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables. The group operates its restaurants in California, Arizona, Hawaii, Nevada, Texas, New York, Oregon, North Carolina, Washington, New Jersey, Florida and South Korea.